AG
LGND icon

Aperio Group’s Ligand Pharmaceuticals LGND Stock Holding History

Aperio Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.84M Buy
29,681
+2,876
+11% +$164K 0.01% 1282
2020
Q3 		$1.59M Sell
26,805
-3,442
-11% -$235K 0.01% 1221
2020
Q2 		$2.11M Sell
30,247
-5,104
-14% -$324K 0.01% 1086
2020
Q1 		$1.6M Buy
35,351
+1,488
+4% +$84.3K 0.01% 1108
2019
Q4 		$2.2M Buy
33,863
+1,386
+4% +$92.6K 0.01% 1044
2019
Q3 		$2.02M Sell
32,477
-1,702
-5% -$107K 0.01% 1057
2019
Q2 		$2.43M Buy
34,179
+569
+2% +$41.9K 0.01% 971
2019
Q1 		$2.64M Sell
33,610
-1,457
-4% -$110K 0.01% 930
2018
Q4 		$2.97M Sell
35,067
-3,798
-10% -$405K 0.02% 829
2018
Q3 		$6.66M Buy
38,865
+637
+2% +$96K 0.03% 581
2018
Q2 		$4.94M Sell
38,228
-919
-2% -$103K 0.02% 671
2018
Q1 		$4.03M Buy
39,147
+707
+2% +$69.9K 0.02% 731
2017
Q4 		$3.28M Buy
38,440
+6,252
+19% +$542K 0.02% 800
2017
Q3 		$2.73M Buy
32,188
+954
+3% +$75.5K 0.02% 821
2017
Q2 		$2.37M Buy
31,234
+16,446
+111% +$1.15M 0.01% 846
2017
Q1 		$976K Buy
14,788
+3,573
+32% +$235K 0.01% 1181
2016
Q4 		$711K Sell
11,215
-1,835
-14% -$116K 0.01% 1311
2016
Q3 		$831K Buy
13,050
+2,215
+20% +$163K 0.01% 1191
2016
Q2 		$806K Buy
10,835
+1,485
+16% +$110K 0.01% 1169
2016
Q1 		$625K Buy
9,350
+2,901
+45% +$176K 0.01% 1258
2015
Q4 		$436K Buy
6,449
+1,098
+21% +$67.8K ﹤0.01% 1410
2015
Q3 		$286K Buy
5,351
+351
+7% +$21.3K ﹤0.01% 1585
2015
Q2 		$315K Buy
5,000
+625
+14% +$34.1K ﹤0.01% 1595
2015
Q1 		$210K Buy
+4,375
New +$168K ﹤0.01% 1805

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Aperio Group's LGND Position: Q4 2020 in Review

Aperio Group increased its Ligand Pharmaceuticals (LGND) stake by 11% in Q4 2020, buying an estimated $164K and bringing the position to 29,681 shares worth $1.84M. The position accounts for 0.01% of the portfolio, ranked #1282.

Aperio Group first reported a position in LGND in Q1 2015 and has held it in 24 quarters since. The position peaked at $6.66M in Q3 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Aperio Group held 29,681 shares of Ligand Pharmaceuticals worth $1.84M as of Q4 2020.
  • Aperio Group bought 2,876 Ligand Pharmaceuticals shares in Q4 2020, an estimated $164K.
  • Ligand Pharmaceuticals made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1282 holding.
  • Aperio Group first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 24 quarters since.
  • Aperio Group's Ligand Pharmaceuticals position peaked at $6.66M in Q3 2018.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.